OICR Series
Predicting Response to Anthracyclines
May 2022
Summary
Developing targeted conventional therapies hampered by lack of understanding key events/pathways that lead to response/resistance
Highlights
- 1
Lack of validated biomarkers
- 2
Co-ordinated molecular analysis of cell lines and clinical trial material has led to identification of histone assay
- 3
Assay has been validated in phase III clinical trial
- 4
Ongoing studies validating assay to level IA and IB
- 5
Histone assay is a potential tool that could be used by clinicians to determine if a patient could be spared anthracycline treatment.
Comments (0)